EOM 1352: Fri 7 June 2024, 11:36

Current Edition

ramusmedical
Europe

Merck plans trio of Phase 3 Keytruda studies in prostate cancer

Merck & Co. said Thursday it plans to launch three pivotal Phase 3 studies testing different combination therapies involving its blockbuster immunotherapy Keytru...
Continue Reading →
news

Intercept NASH drug succeeds in field’s first positive Phase 3 trial

An experimental drug from Intercept Pharmaceuticals helped improve liver scarring in patients with non-alcoholic steatohepatitis, or NASH, in a large Phase 3 st...
Continue Reading →
news

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announce first of its kind collaboration to integrate blockchain technology into clinical trials

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, the...
Continue Reading →
news

Use of clinical apps significantly improves quality of cardiovascular care

A pilot program using several clinical decision support tools in the outpatient setting to treat and educate stable ischemic heart disease patients has shown succes...
Continue Reading →
news

Ochsner Health System and Pfizer partner to develop innovative models for clinical trials

NEW ORLEANS & Ochsner Health System, Louisiana's largest non-profit academic healthcare system, and Pfizer Inc (NYSE:PFE) have entered into a multi-year strateg...
Continue Reading →
news

Orion’s and Bayer’s darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial

American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019: Orion's and Bayer's darolutamide plus androgen deprivation therapy (A...
Continue Reading →
news

AstraZeneca’s MEDI8897 has potential to challenge existing RSV products with substantially improved efficacy, says GlobalData

The FDA recently granted a Breakthrough Therapy designation to AstraZeneca’s MEDI8897. Following several years of clinical development setbacks in the respiratory sy...
Continue Reading →
Europe

Merck’s Keytruda set to become new standard of care for renal cancer patient population after gaining edge over competitors, says GlobalData

Merck & Co Inc’s abstract presentation regarding KEYNOTE-426 trial at ASCO GU 2019 (16 February 2019) has confirmed that Keytruda, an anti-PD-1 therapy, in combi...
Continue Reading →
news

New Clinerion And Citeline Partnership Simplifies and Strengthens Matchmaking Between Clinical Researchers and Qualified Patients

Collaboration between two companies leads to more informed decisions for clinical researchers, grounded in real-world evidence. Citeline, part of the Informa Pharm...
Continue Reading →
news

Our brains indicate how well depression will respond to treatment

(Vienna, 19 February 2019) Working with international partners, a MedUni Vienna research group has shown that imaging techniques carried out prior to treatment indic...
Continue Reading →
Quotient